This is a micro-learning module summary of a presentation by William Callahan, DO which you can find here. Before participating, please read our CME and disclosure information which can be found here.
This program is supported through an independent educational grant from MSD. It is intended for healthcare professionals globally.
Introduction
Clinical decision-making in ASCVD prevention begins by stratifying patients into risk-based groups and aligning treatment intensity with risk. Recommendations are clear for several high-risk groups where lipid-lowering therapy is indicated without the need for further risk estimation.
Risk-Based ASCVD Treatment Decisions
Patients for whom lipid-lowering therapy is indicated without further risk estimation
Patients should be on lipid-lowering therapy when they fall into high-risk categories, including:
- Patients with clinical ASCVD
- Patients with diabetes
- Patients with LDL cholesterol at or above 190 mg/dL
Counselling and patient discussion remain essential, but recommendations consistently support lipid-lowering therapy in these groups.
Patients Requiring Risk Estimation and Shared Decision-Making
For many patients who do not fall into the above high-risk groups, clinicians rely on risk calculation to determine whether a patient is low, intermediate, or high risk. In these cases, risk-enhancing factors become important because commonly used calculators do not capture all contributors to ASCVD risk.
This is where a shared decision-making discussion is required to review factors that may increase risk and to align treatment decisions with patient preferences.
Risk Categories and Treatment Approach (2018 AHA/ACC guidance)
Patients 40-75 years old
Low Risk
- Definition: ASCVD risk <5%
- Recommended Approach: Focus on lifestyle modification
- Key Points:
- Diet quality: Prioritize fiber intake; reduce processed carbohydrates and processed fats.
- Exercise: Increase physical activity.
- Lifestyle Factors: Focus on smoking cessation, stress management, and adequate sleep.
Intermediate Risk
- Definition: ASCVD risk 7.5% to <20%
- Recommended Approach: Shared decision-making
- Key Points:
- Consultation: Discuss individual risk factors and patient preferences.
- Targets: Discuss a target LDL <100 mg/dL.
- Medication: If a statin is initiated, use a moderate-intensity statin to reduce LDL by ~30%.
- Patient Education: Note that cholesterol is often harder for patients to understand than blood pressure or blood glucose because symptoms are not felt.
High Risk
- Definition: ASCVD risk >20%
- Recommended Approach: Pharmacologic therapy
- Key Points:
- Medication: Initiate a high-intensity statin.
- Reduction Goal: Aim for an LDL reduction of $\ge 50%$.
- Diabetes Context: In patients with diabetes, the LDL goal is below 70 mg/dL.
- Advanced Risk: For established ASCVD and high risk of recurrence, goals are shifting toward very low LDL, with recommendations suggesting targets below 55 mg/dL.
Patients under 40 years old
For adults aged 20 to 39, clinicians should still discuss lifestyle and consider shared decision-making about cholesterol-lowering medication when cholesterol is elevated, even when patients do not fall into the highest-risk groups.
If a patient under 40 falls into a high-risk group, such as diabetes or LDL above 190 mg/dL, lipid-lowering therapy is indicated.
Familial hypercholesterolaemia (FH)
Identifying FH requires attention to family history, especially multiple relatives with early heart disease.
Key points to consider:
- People with familial hypercholesterolaemia carry an increased risk of coronary artery disease, even when LDL is reduced below 190 mg/dL.
- Recommendations include screening children with a known family history of familial hypercholesterolaemia.
- If a child’s LDL is above 160 mg/dL in the setting of a positive family history, lipid-lowering therapy should be considered.
- Anyone with LDL above 190 mg/dL should be started on lipid-lowering therapy regardless of family history.
Risk Estimation Tools
2013 Pooled Cohort Equations (PCE) risk calculator: what it includes
Many clinicians use the 2013 PCE calculator, often because it is built into electronic medical records and can automatically pull patient data to generate a risk estimate.
The PCE calculator considers:
- Cholesterol levels
- Smoking status
- Diabetes status
- Hypertension
- Age
- Sex
- Race
A key limitation is that many relevant risk contributors are not included, which is why additional risk factors must be considered in the clinical discussion.
Limitations of the 2013 PCE calculator
Concerns about the calculator relate to the data used to create it.
- It was built using data from approximately 25,000 individuals across several cohorts, with data originating from the 1980s and earlier.
- Studies suggest it can overestimate risk by up to 20%.
In addition, it does not account for multiple important contributors to risk, including:
- Metabolic syndrome
- Chronic kidney disease
- Persistently high triglycerides
- Abnormal ABI
- Social determinants of health
Social determinants of health (SDOH) and ASCVD risk
Social determinants of health are a significant and persistent contributor to ASCVD risk and are not captured by traditional risk calculators. They influence cardiovascular risk independently of, and in addition to, biological risk factors.
Key domains that contribute to cardiovascular risk include social and community context, access to and quality of healthcare, neighborhood and built environment, economic stability, and education access and quality.
At an individual level, lower educational attainment, lower income, and unemployment are associated with higher cardiovascular risk. At an area level, the socioeconomic profile of the neighborhood shapes daily health-related behaviors and opportunities, including access to safe spaces for physical activity, access to grocery stores versus food deserts, perceived and actual safety, and the feasibility of traveling for food or healthcare due to time and transportation constraints.
Higher cumulative burden of adverse social determinants is associated with substantially increased ASCVD risk, with studies indicating up to a 31% higher risk of ASCVD events among individuals with the greatest SDOH burden.
Clinical implications and approaches
Addressing social determinants of health requires a systematic and team-based approach. Effective strategies include educating healthcare teams on how to identify and respond to social risk factors, fostering diversity within care teams to support patient trust and disclosure, and using clear, equitable, and understandable language in patient communication.
Leveraging technology, such as patient portals and simplified scheduling systems, can reduce access barriers. Community engagement initiatives, including outreach and screening activities, can further support trust, access, and early risk identification.
PREVENT calculator
The PREVENT calculator is a newer ASCVD risk assessment tool introduced in 2023. It is derived from cohort and electronic medical record data encompassing over 300 million patient charts. Unlike earlier calculators, it does not include race as a variable.
PREVENT incorporates additional clinical and contextual factors relevant to cardiovascular risk, including kidney function, microalbuminuria, glycaemic status, medication use, and zip code. Zip code is used as a proxy for social determinants of health. By including measures such as GFR, A1C, and microalbumin, the calculator better captures risk related to chronic kidney disease and pre-diabetes.
Evidence indicates that the PREVENT calculator does not overestimate ASCVD risk. It provides both 10-year and 30-year risk estimates, supporting longer-term risk assessment and planning.
Clinical scenario: Mrs Jackson
Mrs Jackson is a 55-year-old white female who presents for a follow-up visit and requests routine blood work. Her family history is unknown because she is adopted. She smokes approximately one quarter pack per day and is attempting to quit. She reports social alcohol use of one to two drinks per week and denies illicit drug use. She lives alone in an apartment in a historically underserved area, has no access to nearby parks, and cannot afford a gym membership. She reports limited access to grocery stores and describes her neighborhood as a grocery store desert. As a result, her diet is high in fast food. She works as a cashier.
Her blood pressure is 140/80 mmHg and her body mass index is 33.2. Laboratory testing shows an LDL cholesterol level of 142 mg/dL, an HDL cholesterol level of 35 mg/dL, a hemoglobin A1C of 6.2, and a glomerular filtration rate of 58.
Using the 2013 ASCVD risk calculator, her estimated 10-year cardiovascular disease risk is 9.1%. She therefore falls into the intermediate-risk category, and the appropriate next step is to initiate a shared decision-making discussion that considers her risk factors and preferences regarding statin therapy.
Comparison of risk calculators in Mrs Jackson
In Mrs Jackson’s case, the 2013 ASCVD risk calculator estimates a 10-year risk of 9.1%. When assessed using the PREVENT calculator, her estimated 10-year risk is 5.0%, with a 30-year risk of 22.0%.
The inclusion of longer-term risk estimates allows for a more comprehensive discussion with the patient about cardiovascular risk and supports shared decision-making regarding risk reduction strategies over time.
Summary
ASCVD treatment decisions are guided by overall cardiovascular risk rather than LDL-C alone. Lipid-lowering therapy is indicated without further risk calculation in patients with established ASCVD, diabetes, or LDL-C ≥190 mg/dL, while patients aged 40–79 years who do not fall into these categories should undergo risk estimation with shared decision-making. Consideration of additional risk-enhancing factors, including social determinants of health and longer-term risk estimates, supports more individualized and effective prevention strategies.
Content is accurate as of the date of release.